Bausch Health Companies Quarterly Income Statements Chart
Quarterly
|
Annual
Bausch Health Companies Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2014-03-31 | 2013-09-30 | 2013-06-30 | 2012-09-30 | 2012-06-30 | 2007-03-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues | ||||||||||||||||||||||||||||||||||||||||||||
| product sales | 2,504,000,000 | 2,227,000,000 | 2,528,000,000 | 2,482,000,000 | 2,379,000,000 | 2,129,000,000 | 2,382,000,000 | 2,213,000,000 | 2,146,000,000 | 1,922,000,000 | 2,175,000,000 | 2,026,000,000 | 1,947,000,000 | 1,898,000,000 | 2,175,000,000 | 2,088,000,000 | 2,076,000,000 | 2,003,000,000 | 2,190,000,000 | 2,111,000,000 | 1,637,000,000 | 1,986,000,000 | 2,198,000,000 | 2,180,000,000 | 2,122,000,000 | 1,989,000,000 | 2,098,000,000 | 2,108,000,000 | 2,100,000,000 | 1,965,000,000 | 2,133,000,000 | 2,186,000,000 | 2,200,000,000 | 2,076,000,000 | 2,388,700,000 | 2,336,100,000 | 2,748,200,000 | 1,851,100,000 | 1,506,421,000 | 1,063,513,000 | 856,892,000 | 748,742,000 | ||
| other revenues | 26,000,000 | 32,000,000 | 31,000,000 | 28,000,000 | 24,000,000 | 24,000,000 | 26,000,000 | 25,000,000 | 21,000,000 | 22,000,000 | 18,000,000 | 20,000,000 | 20,000,000 | 20,000,000 | 21,000,000 | 23,000,000 | 24,000,000 | 24,000,000 | 23,000,000 | 27,000,000 | 27,000,000 | 26,000,000 | 26,000,000 | 29,000,000 | 30,000,000 | 27,000,000 | 23,000,000 | 28,000,000 | 28,000,000 | 30,000,000 | 30,000,000 | 33,000,000 | 33,000,000 | 33,000,000 | 31,500,000 | 35,500,000 | 38,600,000 | 35,100,000 | ||||||
| expenses | ||||||||||||||||||||||||||||||||||||||||||||
| cost of goods sold | 748,000,000 | 683,000,000 | 711,000,000 | 682,000,000 | 708,000,000 | 628,000,000 | 695,000,000 | 612,000,000 | 640,000,000 | 572,000,000 | 645,000,000 | 578,000,000 | 570,000,000 | 543,000,000 | 619,000,000 | 574,000,000 | 604,000,000 | 564,000,000 | 637,000,000 | 578,000,000 | 482,000,000 | 505,000,000 | 622,000,000 | 571,000,000 | 580,000,000 | 524,000,000 | 592,000,000 | 573,000,000 | 584,000,000 | 560,000,000 | 637,000,000 | 650,000,000 | 635,000,000 | |||||||||||
| cost of other revenues | 16,000,000 | 18,000,000 | 16,000,000 | 14,000,000 | 11,000,000 | 12,000,000 | 10,000,000 | 11,000,000 | 9,000,000 | 10,000,000 | 7,000,000 | 6,000,000 | 7,000,000 | 8,000,000 | 7,000,000 | 8,000,000 | 8,000,000 | 10,000,000 | 8,000,000 | 12,000,000 | 13,000,000 | 14,000,000 | 13,000,000 | 13,000,000 | 14,000,000 | 13,000,000 | 10,000,000 | 9,000,000 | 10,000,000 | 13,000,000 | 10,000,000 | 9,000,000 | 11,000,000 | 12,000,000 | 10,500,000 | 9,700,000 | 13,600,000 | |||||||
| selling, general and administrative | 894,000,000 | 867,000,000 | 820,000,000 | 850,000,000 | 832,000,000 | 794,000,000 | 766,000,000 | 715,000,000 | 711,000,000 | 725,000,000 | 666,000,000 | 661,000,000 | 676,000,000 | 622,000,000 | 680,000,000 | 653,000,000 | 685,000,000 | 606,000,000 | 636,000,000 | 572,000,000 | 526,000,000 | 633,000,000 | 668,000,000 | 648,000,000 | 651,000,000 | 587,000,000 | 626,000,000 | 614,000,000 | 642,000,000 | 591,000,000 | 639,000,000 | 623,000,000 | 659,000,000 | 661,000,000 | 671,500,000 | 812,600,000 | 697,600,000 | 482,000,000 | 355,637,000 | 257,373,000 | 188,660,000 | 185,440,000 | ||
| research and development | 159,000,000 | 143,000,000 | 163,000,000 | 146,000,000 | 156,000,000 | 151,000,000 | 152,000,000 | 153,000,000 | 156,000,000 | 143,000,000 | 142,000,000 | 133,000,000 | 127,000,000 | 127,000,000 | 117,000,000 | 121,000,000 | 115,000,000 | 112,000,000 | 119,000,000 | 103,000,000 | 108,000,000 | 122,000,000 | 114,000,000 | 123,000,000 | 117,000,000 | 117,000,000 | 120,000,000 | 107,000,000 | 94,000,000 | 92,000,000 | 90,000,000 | 81,000,000 | 94,000,000 | 96,000,000 | 124,300,000 | 103,100,000 | 101,600,000 | 61,300,000 | 49,009,000 | 24,469,000 | 19,170,000 | 17,711,000 | ||
| amortization of intangible assets | 256,000,000 | 256,000,000 | 259,000,000 | 274,000,000 | 270,000,000 | 274,000,000 | 282,000,000 | 253,000,000 | 269,000,000 | 273,000,000 | 313,000,000 | 290,000,000 | 302,000,000 | 310,000,000 | 320,000,000 | 338,000,000 | 360,000,000 | 357,000,000 | 382,000,000 | 391,000,000 | 436,000,000 | 436,000,000 | 445,000,000 | 475,000,000 | 488,000,000 | 489,000,000 | 502,000,000 | 658,000,000 | 741,000,000 | 743,000,000 | 775,000,000 | 657,000,000 | 623,000,000 | 635,000,000 | 303,598,000 | 218,187,000 | 210,570,000 | |||||||
| asset impairments | 23,000,000 | 5,000,000 | 1,000,000 | 13,500,000 | 4,000,000 | 37,000,000 | 13,000,000 | 4,250,000 | 2,000,000 | 1,000,000 | 14,000,000 | 26,000,000 | 33,000,000 | 13,000,000 | 3,000,000 | 134,000,000 | 89,000,000 | 301,000,000 | 44,000,000 | 85,000,000 | 406,000,000 | 85,000,000 | 138,000,000 | |||||||||||||||||||||
| restructuring, integration and separation costs | 31,000,000 | 1,000,000 | 6,250,000 | 1,000,000 | 12,000,000 | 12,000,000 | 9,000,000 | 12,000,000 | 9,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||
| other income | -18,000,000 | 15,000,000 | 2,000,000 | 225,000,000 | 20,000,000 | 60,000,000 | -83,000,000 | 23,000,000 | 29,000,000 | 4,000,000 | 2,000,000 | 44,000,000 | -183,000,000 | 542,000,000 | -30,000,000 | 308,000,000 | 16,000,000 | 107,000,000 | 23,000,000 | 1,399,000,000 | 10,000,000 | 8,000,000 | -4,000,000 | -17,000,000 | -15,000,000 | 11,000,000 | 231,000,000 | -325,000,000 | -19,000,000 | -240,000,000 | -45,300,000 | 23,100,000 | 30,200,000 | -43,300,000 | ||||||||||
| operating income | 444,000,000 | 276,000,000 | 558,000,000 | 318,000,000 | 389,000,000 | 281,000,000 | 362,000,000 | 14,000,000 | 412,000,000 | 175,000,000 | -236,000,000 | 244,000,000 | 161,000,000 | 285,000,000 | 367,000,000 | 574,000,000 | -270,000,000 | -221,000,000 | -5,000,000 | 460,000,000 | -27,000,000 | 248,000,000 | -1,076,000,000 | 329,000,000 | 257,000,000 | 287,000,000 | 25,000,000 | 117,000,000 | -245,000,000 | -2,281,000,000 | -322,000,000 | 38,000,000 | 175,000,000 | 211,000,000 | 80,500,000 | 66,200,000 | 447,800,000 | 356,600,000 | -891,498,000 | 141,513,000 | 29,464,000 | 86,810,000 | ||
| yoy | 14.14% | -1.78% | 54.14% | 2171.43% | -5.58% | 60.57% | -253.39% | -94.26% | 155.90% | -38.60% | -164.31% | -57.49% | -159.63% | -228.96% | -7440.00% | 24.78% | 900.00% | -189.11% | -99.54% | 39.82% | -110.51% | -13.59% | -4404.00% | 181.20% | -204.90% | -112.58% | -107.76% | 207.89% | -240.00% | -1181.04% | -500.00% | -42.60% | -60.92% | -40.83% | -109.03% | -53.22% | 1419.82% | 310.78% | ||||||
| qoq | 60.87% | -50.54% | 75.47% | -18.25% | 38.43% | -22.38% | 2485.71% | -96.60% | 135.43% | -174.15% | -196.72% | 51.55% | -43.51% | -22.34% | -36.06% | -312.59% | 22.17% | 4320.00% | -101.09% | -1803.70% | -110.89% | -123.05% | -427.05% | 28.02% | -10.45% | 1048.00% | -78.63% | -147.76% | -89.26% | 608.39% | -947.37% | -78.29% | -17.06% | 162.11% | 21.60% | -85.22% | 25.57% | -140.00% | -729.98% | 380.29% | -66.06% | |||
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||||
| interest income | 13,000,000 | 11,000,000 | 9,000,000 | 7,000,000 | 8,000,000 | 9,000,000 | 7,000,000 | 6,000,000 | 7,000,000 | 6,000,000 | 6,000,000 | 3,000,000 | 3,000,000 | 2,000,000 | 1,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 7,000,000 | 3,000,000 | 2,000,000 | 3,000,000 | 4,000,000 | 2,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 2,100,000 | 900,000 | 700,000 | 1,800,000 | 2,686,000 | 1,054,000 | 1,156,000 | 1,020,000 | ||
| interest expense | -465,000,000 | -330,000,000 | -337,000,000 | -346,000,000 | -350,000,000 | -355,000,000 | -363,000,000 | -339,000,000 | -319,000,000 | -307,000,000 | -307,000,000 | -385,000,000 | -410,000,000 | -362,000,000 | -343,000,000 | -351,000,000 | -364,000,000 | -368,000,000 | -379,000,000 | -374,000,000 | -385,000,000 | -396,000,000 | -391,000,000 | -406,000,000 | -409,000,000 | -406,000,000 | -414,000,000 | -420,000,000 | -435,000,000 | -416,000,000 | -448,000,000 | -459,000,000 | -459,000,000 | -474,000,000 | -472,500,000 | -426,600,000 | -420,200,000 | -246,500,000 | -249,306,000 | -176,793,000 | -116,042,000 | -100,614,000 | ||
| gain on extinguishment of debt | 178,000,000 | 12,000,000 | 11,000,000 | 192,000,000 | 570,000,000 | 113,000,000 | ||||||||||||||||||||||||||||||||||||||
| foreign exchange and other | -30,000,000 | -4,000,000 | -21,000,000 | -11,000,000 | -15,000,000 | -14,000,000 | -7,000,000 | -21,000,000 | -10,000,000 | -12,000,000 | 7,000,000 | 4,000,000 | -7,000,000 | -4,000,000 | 3,000,000 | 7,000,000 | 1,000,000 | -4,000,000 | -13,000,000 | -13,000,000 | -4,000,000 | 9,000,000 | 3,000,000 | 5,000,000 | -9,000,000 | 27,000,000 | 20,000,000 | 19,000,000 | 39,000,000 | 29,000,000 | 13,100,000 | -6,200,000 | -34,000,000 | -13,400,000 | 5,079,000 | -10,082,000 | -1,603,000 | -4,238,000 | ||||||
| income before income taxes | 140,000,000 | -47,000,000 | 209,000,000 | -21,000,000 | 48,000,000 | -69,000,000 | -7,000,000 | -326,000,000 | 79,000,000 | -136,000,000 | -357,000,000 | 439,000,000 | -129,000,000 | |||||||||||||||||||||||||||||||
| benefit from income taxes | -12,000,000 | -39,000,000 | -111,000,000 | -71,000,000 | -49,000,000 | -8,000,000 | -45,250,000 | -56,000,000 | 16,000,000 | 77,000,000 | 112,000,000 | 26,000,000 | -47,000,000 | 18,000,000 | 9,000,000 | 74,000,000 | -3,000,000 | 7,200,000 | ||||||||||||||||||||||||||
| net income | 128,000,000 | -86,000,000 | 98,000,000 | -92,000,000 | -1,000,000 | -77,000,000 | -47,000,000 | -382,000,000 | 27,000,000 | -209,000,000 | -410,000,000 | 403,000,000 | -139,000,000 | -66,000,000 | 72,000,000 | 191,000,000 | -593,000,000 | -607,000,000 | -152,000,000 | 70,000,000 | -325,000,000 | -152,000,000 | -1,517,000,000 | -48,000,000 | -170,000,000 | -48,000,000 | -342,000,000 | -351,000,000 | -872,000,000 | -2,691,000,000 | 512,000,000 | 1,300,000,000 | -37,000,000 | 629,000,000 | -304,000,000 | -372,900,000 | 51,700,000 | -20,300,000 | -971,975,000 | 10,866,000 | 7,645,000 | -21,607,000 | ||
| yoy | -12900.00% | 11.69% | -308.51% | -75.92% | -103.70% | -63.16% | -88.54% | -194.79% | -119.42% | 216.67% | -669.44% | 110.99% | -76.56% | -89.13% | -147.37% | 172.86% | 82.46% | 299.34% | -89.98% | -245.83% | 91.18% | 216.67% | 343.57% | -86.32% | -80.50% | -98.22% | -166.80% | -127.00% | 2256.76% | -527.82% | -268.42% | -448.62% | -171.57% | -3198.52% | -68.72% | -3531.81% | 576.26% | -6.05% | ||||||
| qoq | -248.84% | -187.76% | -206.52% | 9100.00% | -98.70% | 63.83% | -87.70% | -1514.81% | -112.92% | -49.02% | -201.74% | -389.93% | 110.61% | -191.67% | -62.30% | -132.21% | -2.31% | 299.34% | -317.14% | -121.54% | 113.82% | -89.98% | 3060.42% | -71.76% | 254.17% | -85.96% | -2.56% | -59.75% | -67.60% | -625.59% | -60.62% | -3613.51% | -105.88% | -306.91% | -18.48% | -821.28% | -354.68% | -97.91% | -9045.10% | 42.13% | -135.38% | |||
| net income margin % | ||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to noncontrolling interest | 20,000,000 | 28,000,000 | 7,750,000 | 7,000,000 | 13,000,000 | -4,000,000 | -6,000,000 | -3,000,000 | -2,000,000 | -3,000,000 | -1,000,000 | -1,000,000 | -4,000,000 | -1,000,000 | ||||||||||||||||||||||||||||||
| net income attributable to bausch health companies inc. | 148,000,000 | -58,000,000 | 93,000,000 | -85,000,000 | 10,000,000 | -64,000,000 | -39,000,000 | -378,000,000 | 26,000,000 | -201,000,000 | -410,000,000 | 399,000,000 | -145,000,000 | -69,000,000 | 69,000,000 | 188,000,000 | -595,000,000 | -610,000,000 | -153,000,000 | 71,000,000 | -326,000,000 | -152,000,000 | -1,516,000,000 | -49,000,000 | -171,000,000 | -52,000,000 | -344,000,000 | -350,000,000 | -873,000,000 | |||||||||||||||
| earnings per share attributable to bausch health companies inc. | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.46 | 3.71 | -0.11 | 1.8 | -0.88 | -1.08 | 0.14 | -2.92 | |||||||||||||||||||||
| diluted | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.45 | 3.69 | -0.11 | 1.79 | -0.88 | -1.08 | 0.14 | -2.92 | |||||||||||||||||||||
| weighted-average common shares | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 370.9 | 367.9 | 365.4 | 364.8 | 362.5 | 359.6 | 355.6 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 350.2 | 350.4 | 350.1 | 349.8 | 345 | 344.9 | 344.9 | 333,643 | 308,153 | 304,075 | 304,816 | ||||||||||||||||||||
| diluted | 373.1 | 370.2 | 365.4 | 367.1 | 363.4 | 364 | 357.8 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 351.8 | 352.3 | 350.1 | 350.5 | 345 | 344.9 | 351 | 333,643 | 314,447 | 311,743 | 304,816 | ||||||||||||||||||||
| basic and diluted loss per share attributable to bausch health companies inc. | -0.16 | 0.25 | -0.23 | -0.17 | -0.55 | -0.4 | -0.19 | -1.66 | -1.71 | -0.92 | -0.43 | -0.193 | -0.14 | |||||||||||||||||||||||||||||||
| basic and diluted weighted-average common shares | 369.6 | 368 | 368.4 | 366.8 | 364.9 | 363.3 | 362 | 362.2 | 360.8 | 358.9 | 359.1 | 356.8 | 355 | 355.3 | 353.4 | 352.4 | 352.1 | |||||||||||||||||||||||||||
| goodwill impairments | 91,000,000 | 402,000,000 | 622,000,000 | 119,000,000 | 83,000,000 | 469,000,000 | 109,000,000 | 2,213,000,000 | 312,000,000 | |||||||||||||||||||||||||||||||||||
| net income (income) attributable to noncontrolling interest | 11,000,000 | 8,000,000 | 4,000,000 | 8,000,000 | 1,000,000 | -500,000 | 1,000,000 | |||||||||||||||||||||||||||||||||||||
| restructuring, integration, separation and ipo costs | 22,000,000 | 14,000,000 | 16,000,000 | 10,000,000 | 5,000,000 | 10,000,000 | 35,000,000 | 13,000,000 | 21,000,000 | 8,000,000 | ||||||||||||||||||||||||||||||||||
| (benefit from) benefit from income taxes | -52,000,000 | -73,000,000 | -53,000,000 | -36,000,000 | -10,000,000 | 9,000,000 | -25,000,000 | -16,000,000 | 33,250,000 | -5,000,000 | -18,500,000 | -51,000,000 | -138,000,000 | |||||||||||||||||||||||||||||||
| net (income) loss attributable to noncontrolling interest | -1,000,000 | -2,000,000 | -3,000,000 | -1,500,000 | -1,000,000 | |||||||||||||||||||||||||||||||||||||||
| asset impairments, including loss on assets held for sale | 1,000,000 | 6,000,000 | 8,000,000 | 21,000,000 | 18,000,000 | 47,000,000 | 148,000,000 | |||||||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -12,000,000 | -45,000,000 | -5,000,000 | -8,000,000 | -27,000,000 | -24,000,000 | -2,000,000 | -33,000,000 | -7,000,000 | -44,000,000 | -48,000,000 | -27,000,000 | -57,000,000 | -1,000,000 | -64,000,000 | -93,700,000 | -8,161,000 | -2,322,000 | ||||||||||||||||||||||||||
| income before benefit from income taxes | -82,000,000 | 21,000,000 | 216,000,000 | -670,000,000 | -591,000,000 | -394,000,000 | 75,000,000 | -437,000,000 | -178,000,000 | -1,470,000,000 | -66,000,000 | -179,000,000 | -122,000,000 | -426,000,000 | -300,000,000 | -734,000,000 | -2,694,000,000 | -365,700,000 | ||||||||||||||||||||||||||
| acquisition-related contingent consideration | 22,000,000 | 2,000,000 | 11,000,000 | 13,000,000 | 10,000,000 | 3,000,000 | 20,000,000 | -21,000,000 | 14,000,000 | -19,000,000 | -6,000,000 | 2,000,000 | 8,000,000 | -238,000,000 | -49,000,000 | -10,000,000 | 6,900,000 | 2,400,000 | 3,800,000 | 8,900,000 | -34,995,000 | 3,669,000 | 5,630,000 | 7,729,000 | ||||||||||||||||||||
| restructuring and integration costs | 7,000,000 | 4,000,000 | 3,000,000 | 4,000,000 | 4,000,000 | 20,000,000 | 6,000,000 | 3,000,000 | 7,000,000 | 6,000,000 | 10,000,000 | 6,000,000 | 18,000,000 | 18,000,000 | ||||||||||||||||||||||||||||||
| basic and diluted loss per share attributable to bausch health companies inc.: | -0.49 | |||||||||||||||||||||||||||||||||||||||||||
| acquired in-process research and development costs | 1,000,000 | 1,000,000 | 1,000,000 | 4,000,000 | ||||||||||||||||||||||||||||||||||||||||
| loss per share attributable to bausch health companies inc.: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | -0.15 | |||||||||||||||||||||||||||||||||||||||||||
| diluted | -0.15 | |||||||||||||||||||||||||||||||||||||||||||
| earnings per share attributable to bausch health companies inc.: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.46 | 3.71 | -0.11 | 1.8 | -0.88 | -1.08 | 0.14 | -2.92 | |||||||||||||||||||||
| diluted | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.45 | 3.69 | -0.11 | 1.79 | -0.88 | -1.08 | 0.14 | -2.92 | |||||||||||||||||||||
| less: net income attributable to noncontrolling interest | 2,000,000 | 250,000 | -1,000,000 | 1,000,000 | 1,000,000 | -1,700,000 | 800,000 | 2,200,000 | 2,300,000 | 1,268,000 | ||||||||||||||||||||||||||||||||||
| net income attributable to valeant pharmaceuticals international, inc. | -2,693,000,000 | 513,000,000 | 1,301,000,000 | -38,000,000 | 628,000,000 | -302,300,000 | -373,700,000 | 49,500,000 | -22,600,000 | -973,243,000 | ||||||||||||||||||||||||||||||||||
| earnings per share attributable to valeant pharmaceuticals international, inc.: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.46 | 3.71 | -0.11 | 1.8 | -0.88 | -1.08 | 0.14 | -2.92 | |||||||||||||||||||||
| diluted | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.45 | 3.69 | -0.11 | 1.79 | -0.88 | -1.08 | 0.14 | -2.92 | |||||||||||||||||||||
| income before recovery of income taxes | -234,250,000 | -400,000,000 | -242,000,000 | -1,141,200,000 | -89,347,000 | |||||||||||||||||||||||||||||||||||||||
| recovery of income taxes | -707,250,000 | -1,700,000,000 | -205,000,000 | -169,225,000 | -96,992,000 | |||||||||||||||||||||||||||||||||||||||
| cost of goods sold (excluding amortization and impairments of | ||||||||||||||||||||||||||||||||||||||||||||
| intangible assets) | 584,000,000 | |||||||||||||||||||||||||||||||||||||||||||
| income before (recovery of) benefit from income taxes | -295,000,000 | -376,800,000 | -5,700,000 | |||||||||||||||||||||||||||||||||||||||||
| (recovery of) benefit from income taxes | -924,000,000 | -72,800,000 | -57,400,000 | |||||||||||||||||||||||||||||||||||||||||
| operating expenses | ||||||||||||||||||||||||||||||||||||||||||||
| cost of goods sold (exclusive of amortization and impairments of | ||||||||||||||||||||||||||||||||||||||||||||
| finite-lived intangible assets shown separately below) | 647,300,000 | 620,200,000 | 634,600,000 | 504,100,000 | 560,855,000 | |||||||||||||||||||||||||||||||||||||||
| amortization and impairments of finite-lived intangible assets | 887,600,000 | 694,500,000 | 679,200,000 | 355,200,000 | 910,248,000 | |||||||||||||||||||||||||||||||||||||||
| restructuring, integration and other costs | 19,500,000 | 38,000,000 | 75,600,000 | 133,600,000 | 295,890,000 | 53,665,000 | 42,872,000 | 30,004,000 | ||||||||||||||||||||||||||||||||||||
| in-process research and development impairments and other charges | 17,400,000 | 95,800,000 | 12,000,000 | 123,981,000 | 4,830,000 | |||||||||||||||||||||||||||||||||||||||
| acquisition-related costs | 1,800,000 | 7,000,000 | 1,500,000 | 8,650,000 | 7,879,000 | 4,605,000 | 13,867,000 | |||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 370.9 | 367.9 | 365.4 | 364.8 | 362.5 | 359.6 | 355.6 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 350.2 | 350.4 | 350.1 | 349.8 | 345 | 344.9 | 344.9 | 333,643 | 308,153 | 304,075 | 304,816 | ||||||||||||||||||||
| diluted | 373.1 | 370.2 | 365.4 | 367.1 | 363.4 | 364 | 357.8 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 351.8 | 352.3 | 350.1 | 350.5 | 345 | 344.9 | 351 | 333,643 | 314,447 | 311,743 | 304,816 | ||||||||||||||||||||
| gain on investments | 3,963,000 | -35,000 | ||||||||||||||||||||||||||||||||||||||||||
| cost of alliance and service revenues | 14,300,000 | 14,353,000 | 14,459,000 | 10,582,000 | 12,483,000 | |||||||||||||||||||||||||||||||||||||||
| income before benefit from (recovery of) income taxes | 4,800,000 | -17,057,000 | ||||||||||||||||||||||||||||||||||||||||||
| benefit from (recovery of) income taxes | 25,100,000 | 4,550,000 | ||||||||||||||||||||||||||||||||||||||||||
| loss per share attributable to valeant pharmaceuticals international, inc.: | ||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -0.07 | |||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares | ||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | 334.9 | |||||||||||||||||||||||||||||||||||||||||||
| alliance and royalty | 16,471,000 | 13,922,000 | 12,248,000 | 56,869,000 | ||||||||||||||||||||||||||||||||||||||||
| service and other | 18,839,000 | 18,327,000 | 15,000,000 | 14,479,000 | ||||||||||||||||||||||||||||||||||||||||
| legal settlements and related fees | 149,601,000 | 1,124,000 | ||||||||||||||||||||||||||||||||||||||||||
| cost of goods sold (exclusive of amortization of | ||||||||||||||||||||||||||||||||||||||||||||
| intangible assets shown separately below) | 283,183,000 | 219,670,000 | 197,284,000 | |||||||||||||||||||||||||||||||||||||||||
| income before (recovery of ) benefit from income taxes | -40,345,000 | |||||||||||||||||||||||||||||||||||||||||||
| (recovery of ) benefit from income taxes | -51,211,000 | |||||||||||||||||||||||||||||||||||||||||||
| basic earnings per share | 0.04 | 0.03 | -0.07 | |||||||||||||||||||||||||||||||||||||||||
| diluted earnings per share | 0.03 | 0.02 | -0.07 | |||||||||||||||||||||||||||||||||||||||||
| acquired in-process research and development | 145,300,000 | 4,568,000 | ||||||||||||||||||||||||||||||||||||||||||
| legal settlements | 53,624,000 |
We provide you with 20 years income statements for Bausch Health Companies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Bausch Health Companies stock. Explore the full financial landscape of Bausch Health Companies stock with our expertly curated income statements.
The information provided in this report about Bausch Health Companies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.